NCT05457829View on ClinicalTrials.gov

Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions
Rhabdomyosarcoma, Child
Interventions
DRUG

Doxorubicin Hydrochloride Liposome+Irinotecan

Q3W, 2 cycles.

DRUG

Temozolomide+Irinotecan+Vincristine

Q3W, 2 cycles.

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sun Yat-sen University

OTHER

NCT05457829 - Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study | Biotech Hunter | Biotech Hunter